What question did this study set out to answer?

To describe prospective and balanced alpha allocation methods for elevating a distinct genetic subgroup analysis to a co-primary endpoint alongside the full cohort in the COAG trial.

August 6, 2010Clinical TrialsOpen Access

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

View Full Paper

Ask AI

Bookmark

Why the study?

Does a genotype-guided dosing algorithm improve anticoagulation status compared to a clinical-only algorithm in patients initiating warfarin?

Population

Patients initiating warfarin treatment (COAG trial design)

Comparison

Genotype-guided dosing algorithm to initiate… vs Dosing algorithm using only clinical information

Design

Other, randomized, double-blinded

Authors

JJJungnam JooNational Institutes of Health NGNancy L. GellerGeneral Cardiology BFBenjamin FrenchCardiac Imaging

Discussion

Member takes

Implication

May facilitate co-primary subgroup testing in genotype-guided trials; extends power methods but leaves clinical adoption open.

Key Points

To describe prospective and balanced alpha allocation methods for elevating a distinct genetic subgroup analysis to a co-primary endpoint alongside the full cohort in the COAG trial.
Designed a statistical allocation framework for a multicenter, double-blind, randomized trial comparing genotype-guided versus clinical-only warfarin dosing algorithms.
Formulated mathematical approaches for prospective alpha allocation and balanced alpha allocation to achieve equal target power across full-cohort and subgroup primary analyses.
Incorporating the correlation between the full cohort and subgroup analyses improved statistical power for the subgroup comparison without inflating type I error.
Achieved identical prespecified statistical power across both co-primary endpoints through a balanced alpha allocation approach using estimated trial parameters.

Structured PICO

Does a genotype-guided dosing algorithm improve anticoagulation status compared to a clinical-only algorithm in patients initiating warfarin?

Population

Patients initiating warfarin treatment (COAG trial design)

Intervention

Genotype-guided dosing algorithm (using clinical and genetic information) to initiate warfarin treatment

Comparator

Dosing algorithm using only clinical information

Outcome

Anticoagulation statussurrogate

This statistical methodology paper outlines a balanced alpha allocation approach to improve power for co-primary analyses in the full cohort and a genetically-defined subgroup in the COAG trial.

Limitations

Impractical to stratify the randomization on subgroup membership because genetic information may not be available at the time of randomization

Cite This Study

Joo et al. (2010) studied this question.

synapsesocial.com/papers/6a7002fc75498292b7096458 https://doi.org/10.1177/1740774510381285

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider